Email
Contact Information
Laura Wood
Guinness Enterprise Centre
Dublin,
+353-1-415-1258
Press Release Spread
Biobetters: Major Players and Market Prospects - Marketing Gimmick or Natural Evolution?
Biobetters: Major Players and Market Prospects - Marketing Gimmick or Natural Evolution?
For some, biobettersdrugs similar but superior to the branded reference productare little more than the natural outcome of a drug's life-cycle management strategy.
Even so, interest in biobetters is increasing, since they can and will command higher prices while providing a significant improvement to the reference drug. At the forefront of those turning to biobetters are branded pharma, biotech and large generic companies who have already established themselves in the biosimilars industry. But will the emerging biobetter industry prove to be more lucrative than has been the case for biosimilars?
Report Overview
In Biobetters: Major Players and Market Prospects (2nd edition), FirstWord describes the biobetters market and how interest has mounted in what is still a very young market. The report reviews the role biosimilars have played, presents the rationale behind biobetters and how interest is is stirring in their development. In addition, the report concisely outlines how companies are evolving biobetters, the areas of greatest potential and reviews the Achilles Heel' of immunogenicity. Based on frontline expert interviews, the report addresses the question of approval pathways, who the major players are and, perhaps most importantly, offers a compelling picture of biobetters' future prospects.
Key features
- A comprehensive overview of the nascent biobetters market and where it is going
- An outline of what biobetters are, how they are being developed and what their likely targets are
- A discussion of the regulatory landscape
- An insight into the biobetters manufacturers of tomorrow
- An overview of optimal strategies for success
Key Questions Asked
- How do second generation biologics vary from biobetters proper?
- Will biobetters go through an abbreviated or full new drug approval pathway?
- Who will be the pioneers of the biobetter industry and what is spurring their success?
- How is interest by third-party manufacturers affecting the development of superior biosimilars?
- How is the risk of immunogenicity affecting the case for branded biotech?
- What areas of improvement exist for creating improved biobetters?
Key Topics Covered:
Executive summary
Brands, Biosimilars, and Biobetters
Comparison of international list prices for MabThera/Rituxan
Biobetters - new name for an old drug?
Conclusion
Acknowledgements
For more information visit http://www.researchandmarkets.com/research/4a81f7/biobetters_major
Contact: Laura Wood, Senior Manager,
, U.S. Fax: 646-607-1907
,
Category: Health
Word Count:0
Tags: success key questions, reference drug, mabthera rituxan biobetters, key, market prospects 2, Report, approval pathways, biobetters manufacturers, report addresses, biobetters key topics, biobetter industry, biosimilar, drug approval pathway, party manufacturers, frontline expert interviews, key features, industry, Drug, biobetters market, generation biologics, natural evolution, market, biobetters major players, biobetter, interest, role biosimilars, edition report, reference productare, list prices, biobetters comparison, edition firstword, biobetters future prospects, report reviews, achilles heel, drug conclusion acknowledgements, biosimilars industry, Prospect, major, player, biosimilars report overview
Weblinks: http://www.researchandmarkets.com/research/4a81f7/biobetters_major
Research and Markets
We are the world's leading source for market research and market data, and we hold over 700,000 major research publications from leading publishers, consultants and analysts worldwide. We can provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. We are a one-stop shop for market research reports and industry newsletters from specialist research firms and niche market analysts, and we have clients in over 100 cities worldwide.
Disclaimer